Articles On Opthea (ASX:OPT)

The All Ordinaries index may be up materially this year, but some members of the index have thoroughly outperformed it. The two best performers on the index this year are listed below. Here’s why they are both up over 400% since the turn o...

In afternoon trade the S&P/ASX 200 index is on course to finish a volatile week on a positive note. At the time of writing the benchmark index is up 0.2% to 6,582 points. Four shares that have failed to follow the market higher today a...

Opthea (ASX: OPT) doubled on Wednesday after announcing its anti-AMD treatment (OPT-302) worked; but as CEO Megan Baldwin said yesterday, this was just the start. The announcement was just initial results of the trial – more detailed result...

Opthea (ASX:OPT), an Australian clinical-stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, has reported positive results from its Phase 2b trial of OPT-302 for wet age-related macular degener...

On Stockhead today – the final wrap from Diggers and Dealers, the feds are finally on board with legal pot, and investors want ASIC to find some backbone. But first here’s what you need to know.   The day ahead If there’s one thing we can b...

The Australian share market returned to form on Wednesday following two consecutive days of heavy declines. This led to a number of shares pushing higher with the market, but some more than most. The three high-flying shares listed below h...

A one-day gain of 148 per cent has Opthea as comfortably the best-performing small cap health or biotech stock on the ASX at a time when the majority are trending downwards. Stockhead reported today on Opthea’s (ASX:OPT) positive results fr...

The ASX staged a recovery rally today after a sharp fall yesterday. Here’s some of the top performing ASX shares today. And today’s best performer was…Opthea Limited [ASX:OPT] The Opthea share price had a field day, going up by 136.99% in t...

The Opthea Ltd (ASX: OPT) share price has rocketed 130% to $2.02 this morning after it reported its OPT-302 combination therapy met the primary endpoint in a Phase 2b clinical trial.  According to the announcement the: “OPT-302 + Lucentis...

In afternoon trade the S&P/ASX 200 index has given back a good portion of its morning gains but remains on course to finish the day in positive territory. At the time of writing the index is up 0.15% to 6,488.1 points. Four shares that...

Opthea (ASX: OPT) shares have more than doubled this morning after announcing its Phase IIb clinical trial was a success. The 366-patient study tested its OPT-302 drug, which battles wet (neovascular) age-related macular degeneration (AMD)...

Biopharmaceutical company Opthea (ASX: OPT) has taken an affirmative step towards commercialising its OPT-302 combination therapy after publishing positive phase 2b clinical trial results that included 366 patients. With the results publish...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

The Althea Group Holdings Ltd (ASX: AGH) share price could be on a high on Wednesday following the release of a very positive patient update by the cannabis company this morning. What was announced? This morning Althea provided an update i...

The Opthea Ltd (ASX: OPT) share price will return from its trading halt this morning and could surge higher following the release of a very positive announcement by the developer of novel biologic therapies for the treatment of eye disease...

On Stockhead today – mining lithium from seawater, our monthly dairy stocks update, and why Hot Copper’s not leading the stocks chat space anymore. But first here’s what you need to know. The day ahead It’s the final day of Diggers and Deal...

Opthea (ASX:OPT) is scheduled to update investors tomorrow on the ongoing Phase 2b trial of OPT-302 for wet age-related macular degeneration (AMD).

30 Jul 2019 - Ophthalmic disease therapies company, Opthea (ASX:OPT) has today announced that the European Patent Office (EPO) intends to grant a patent covering one of Opthea's OP…

Opthea (ASX:OPT) has announced that the timing of the primary analysis from its ongoing Phase 2b trial of OPT-302 for wet age-related macular degeneration (AMD) will be brought forward by one quarter.

Companies and institutions that provide medical assistance and services, manufactures of medical equipment, engage in clinical trials and development of drugs, are part of the healthcare sector. The Australian government makes significant c...